Infex Therapeutics

ALDERLEY PARK, Cheshire, U.K. — September 8, 2026 Infex Therapeutics presented new data from its Phase IIa study of...

Alderley Park, Cheshire, U.K., August 19, 2026 Infex Therapeutics will present new Phase IIa data for RESP-X (INFEX702) in...

Alderley Park, Cheshire, U.K., May 21, 2026 Infex Therapeutics announced positive Phase IIa clinical trial results for RESP-X (INFEX702)...